32 research outputs found
Paediatric and adult congenital cardiology education and training in Europe
Background: Limited data exist on training of European paediatric and adult congenital cardiologists. Methods: A structured and approved questionnaire was circulated to national delegates of Association for European Paediatric and Congenital Cardiology in 33 European countries. Results: Delegates from 30 countries (91%) responded. Paediatric cardiology was not recognised as a distinct speciality by the respective ministry of Health in seven countries (23%). Twenty countries (67%) have formally accredited paediatric cardiology training programmes, seven (23%) have substantial informal (not accredited or certified) training, and three (10%) have very limited or no programme. Twenty-two countries have a curriculum. Twelve countries have a national training director. There was one paediatric cardiology centre per 2.66 million population (range 0.87-9.64 million), one cardiac surgical centre per 4.73 million population (range 1.63-10.72 million), and one training centre per 4.29 million population (range 1.63-10.72 million population). The median number of paediatric cardiology fellows per training programme was 4 (range 1-17), and duration of training was 3 years (range 2-5 years). An exit examination in paediatric cardiology was conducted in 16 countries (53%) and certification provided by 20 countries (67%). Paediatric cardiologist number is affected by gross domestic product (R-2 = 0.41). Conclusion: Training varies markedly across European countries. Although formal fellowship programmes exist in many countries, several countries have informal training or no training. Only a minority of countries provide both exit examination and certification. Harmonisation of training and standardisation of exit examination and certification could reduce variation in training thereby promoting high-quality care by European congenital cardiologists.Developmen
Sex differences in health and mortality in Moscow and Denmark
Oksuzyan A, Shkolnikova M, Vaupel JW, Christensen K, Shkolnikov VM. Sex differences in health and mortality in Moscow and Denmark. European Journal of Epidemiology. 2014;29(4):243-252
NEW CRYSTALLINE POLYMORPHIC FORM OF GLYPHOSATE: SYNTHESIS, CRYSTAL AND MOLECULAR STRUCTURES OF N
Perceived stress and biological risk: is the link stronger in Russians than in Taiwanese and Americans?
Metal Carboxylate-Phosphonate Hybrid Layered Compounds: Synthesis and Single Crystal Structures of Novel Divalent Metal Complexes with N
The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome.
Background—Data on the Jervell and Lange-Nielsen syndrome (J-LN), the long-QT syndrome (LQTS) variant associated with deafness and caused by homozygous or compound heterozygous mutations on the KCNQ1 or on the KCNE1 genes encoding the IKs current, are still based largely on case reports.
Methods and Results—We analyzed data from 186 J-LN patients obtained from the literature (31%) and from individual physicians (69%). Most patients (86%) had cardiac events, and 50% were already symptomatic by age 3. Their QTc was markedly prolonged (55765 ms). Most of the arrhythmic events (95%) were triggered by emotions or exercise. Females are at lower risk for cardiac arrest and sudden death (CA/SD) (hazard ratio, 0.54; 95% CI, 0.34 to 0.88; P0.01). A QTc 550 ms and history of syncope during the first year of life are independent predictors of subsequent
CA/SD. Most mutations (90.5%) are on the KCNQ1 gene; mutations on the KCNE1 gene are associated with a more
benign course. -Blockers have only partial efficacy; 51% of the patients had events despite therapy and 27% had
CA/SD.
Conclusions—J-LN syndrome is a most severe variant of LQTS, with a very early onset and major QTc prolongation, and in which -blockers have limited efficacy. Subgroups at relatively lower risk for CA/SD are identifiable and include
females, patients with a QTc 550 ms, those without events in the first year of life, and those with mutations on KCNE1.
Early therapy with implanted cardioverter/defibrillators must be considered